---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-018419"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:57:57.186810+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS

## Summary
- License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.
- Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.
- Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.
- Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.
- Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days.

## SEC filing metadata
- accession: 0000950170-25-018419
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/0000950170-25-018419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/tivc-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-018419
- JSON: https://secwatch.observer/filing/0000950170-25-018419.json
- Plain text: https://secwatch.observer/filing/0000950170-25-018419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.